Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core

The use of p53-MDM2 inhibitors is a prospective strategy in anti-cancer therapy for tumors expressing wild type p53 protein. In this study, we have applied a simple approach of two-step synthesis of imidazoline-based alkoxyaryl compounds, which are able to efficiently inhibit p53-MDM2 protein–protei...

Descripción completa

Detalles Bibliográficos

Autores principales:	Daniil R. Bazanov, Nikolay V. Pervushin, Egor V. Savin, Michael D. Tsymliakov, Anita I. Maksutova, Victoria Yu. Savitskaya, Sergey E. Sosonyuk, Yulia A. Gracheva, Michael Yu. Seliverstov, Natalia A. Lozinskaya, Gelina S. Kopeina
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2022-04-01
Colección:	Pharmaceuticals
Materias:	nutlins cis-imidazolines p53-MDM2 inhibitors anti-cancer
Acceso en línea:	https://www.mdpi.com/1424-8247/15/4/444
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!